Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 6/20 | 0.49 |
| ▸ | MELK | Q14680 | 1/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20267284 | 1.00 | BCL6 (0.49) | BCL6MELKNCOR2TDP1CYP19A1 | |
| SCHEMBL22463721 | 0.89 | CYP19A1 (0.42) | BCL6MELKNCOR2TDP1CYP19A1 | |
| SCHEMBL28555880 | 0.88 | ALDH1A1 (0.48) | BCL6MELKNCOR2CYP19A1MEN1 | |
| SCHEMBL28555882 | 0.88 | ALDH1A1 (0.48) | BCL6MELKNCOR2CYP19A1MEN1 | |
| SCHEMBL21774713 | 0.88 | PTGS2 (0.46) | CYP19A1MEN1KMT2APOLBRXFP1 | |
| SCHEMBL23250037 | 0.87 | CYP19A1 (0.46) | BCL6CYP19A1MEN1KMT2APOLB | |
| SCHEMBL29874201 | 0.87 | CYP19A1 (0.46) | BCL6CYP19A1MEN1KMT2APOLB | |
| SCHEMBL28548429 | 0.87 | PTGDR2 (0.50) | TDP1CYP19A1MEN1KMT2APOLB | |
| SCHEMBL30414767 | 0.87 | PTGDR2 (0.50) | TDP1CYP19A1MEN1KMT2APOLB | |
| SCHEMBL21787543 | 0.87 | ADORA2A (0.43) | BCL6MELKTDP1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096706-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250074890-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| CN-119019369-A | Bifunctional molecules comprising an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety | 阿尔维纳斯运营股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-115397821-B | Bifunctional molecules comprising an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety | 阿尔维纳斯运营股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| EP-4380919-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | Dana-Farber Cancer Institute, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-117980290-A | Cyanopyridine and cyanopyrimidine BCL6 degrading agents | 达纳－法伯癌症研究所公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-112538083-B | Aromatic ring penta aromatic heterocyclic micromolecule organic compound targeting BCL6, derivative thereof and application thereof | 华东师范大学 | 2023-04-28 | — | — | CN | disclosed |
| WO-2023015164-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-4045496-A1 | BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY | Arvinas Operations, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074890-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | BCL6, BCL6B, BCOR | BCL6 1/4885MELK 1332/4885NCOR2 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.